Literature DB >> 3742163

Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias.

K Hashimoto, H Mitsuhashi.   

Abstract

OPC-8212, a positive inotropic agent that increases intracellular cyclic AMP and stimulates the Ca current, was compared with amrinone and AR-L 115 in their effects on canine ventricular arrhythmias. OPC-8212, up to 3 mg kg-1, did not worsen 24 h coronary ligation arrhythmias, while it aggravated ventricular arrhythmias seen 48 h after coronary ligation. However, OPC-8212 did not at any time induce ventricular fibrillation in dogs subjected to coronary ligation. OPC-8212, up to 3 mg kg-1, had no arrhythmogenic or antiarrhythmic effect on digitalis-induced arrhythmias, while amrinone and AR-L 115 showed antiarrhythmic effects. With adrenaline-induced arrhythmias, the three drugs aggravated ventricular tachycardia to produce ventricular fibrillation. The absence of a worsening effect of the new positive inotropic agents on digitalis arrhythmia may be helpful in clinical setting of combined therapy of these new drugs with digitalis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742163      PMCID: PMC1917090          DOI: 10.1111/j.1476-5381.1986.tb16266.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

Review 1.  Cardiac arrhythmias.

Authors:  P F Cranefield; A L Wit
Journal:  Annu Rev Physiol       Date:  1979       Impact factor: 19.318

2.  Effects of AR-L 115 BS, a new cardiotonic compound, on cardiac contractility, heart rate and blood pressure in anaesthetized and conscious animals.

Authors:  W Diederen; R Kadatz
Journal:  Arzneimittelforschung       Date:  1981

3.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

4.  Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia.

Authors:  K Hashimoto; H Satoh; T Shibuya; S Imai
Journal:  J Pharmacol Exp Ther       Date:  1982-12       Impact factor: 4.030

5.  Electrophysiological actions of amrinone in dogs with cardiac lesions.

Authors:  R W Piwonka; J F Healey; P C Canniff; A E Farah
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

6.  Effective plasma concentrations of aprindine in canine ventricular arrhythmias.

Authors:  K Hashimoto; S Komori; M Ishii; J Kamiya
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jan-Feb       Impact factor: 3.105

7.  Effective plasma concentrations of antiarrhythmic drugs against sustained halothane-adrenaline arrhythmia in dogs.

Authors:  T Shibuya; K Hashimoto; S Imai
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jul-Aug       Impact factor: 3.105

8.  In vitro electrophysiologic properties of amrinone in mammalian cardiac tissue.

Authors:  R W Piwonka; P C Canniff; A E Farah
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

9.  Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.

Authors:  K Hashimoto; M Ishii; S Komori; H Mitsuhashi
Journal:  Heart Vessels       Date:  1985-02       Impact factor: 2.037

10.  Antiarrhythmic plasma concentrations of mexiletine on canine ventricular arrhythmias.

Authors:  K Hashimoto; M Ishii; S Komori
Journal:  J Cardiovasc Pharmacol       Date:  1984 Mar-Apr       Impact factor: 3.105

View more
  2 in total

1.  Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness?

Authors:  K Hashimoto; A Haruno; T Matsuzaki; A Sugiyama; K Akiyama
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

2.  OPC-8212 in the treatment of congestive heart failure: results of a pilot study.

Authors:  S H Kubo; T S Rector; J E Strobeck; J N Cohn
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.